Cereno will partner with PHA Europe & Global on patient-centered drug design for pulmonary hypertension medications.

Camp del Corazon and others are made for children with complex health conditions, writes columnist Jolie Lizana.

Living with PH and transplant often involves a lack of privacy, but columnist Anna Jeter has found ways to preserve her ...

Tectonic sees top-line results from a Phase 2 trial of TX45 in PH with heart failure with preserved ejection fraction by ...

Mannkind and United Therapeutics are creating an inhaled formulation of ralinepag, an experimental oral PAH treatment.

Treatment with treprostinil led to significant and sustained improvements in children with PH associated with lung disease, ...

“This study provides comprehensive preclinical evidence that the novel PDE5 inhibitor CPD1 is a potent therapeutic candidate ...

The analysis revealed dozens of genes with abnormal expression in cells from people with idiopathic PAH, and the researchers ...

Pulmonary hypertension (PH) is caused by high blood pressure in the lungs, which is caused by narrowed and thickened pulmonary arteries. Because of the added effort needed to pump blood through the ...

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Treatment with mosliciguat, an inhaled medication given once-daily for pulmonary hypertension (PH), can safely reduce the resistance against blood flow in blood vessels of the lungs, according to a ...

Pulmonary hypertension is a rare lung disease characterized by increased blood pressure in the pulmonary arteries that eventually makes breathing very difficult. Breathing is the most important thing ...